长春瑞滨软胶囊单药节拍化疗一线治疗老年非小细胞肺癌临床疗效观察
DOI: 10.3971/j.issn.1000-8578.2018.18.0841
Keywords: A Meta-analysis,Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer,Progress of Apatinib in Treatment of Non-small Cell Lung Cancer,Research Progress of Biomarkers for Immunotherapy on Non-small Cell Lung Cancer,Expression of β1,3-N-acetylglucosaminyltransferase-3 in Non-small Cell Lung Cancer and Its Clinical Significance,High-doses Granulocyte Colony-stimulating Factor (G-CSF) Benefit Elderly Patients with Acute Myeloid Leukemia,Construction of pcDNA3.1-CD74-ROS1 Recombinant Plasmid and Effect of CD74-ROS1 Expression on Proliferation and Migration of Lung Cancer Cells,Clinicopathological Features, Treatment and Prognosis of Invasive Breast Cancer Patients over 70 Years Old,Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients,Research Progress on Brain Metastases to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-mutated Non-small Cell Lung Cancer Patients
Abstract:
摘要 目的 探讨口服长春瑞滨软胶囊单药节拍化疗在老年非小细胞肺癌患者中的临床疗效及生存时间分析。方法 选择56例年龄≥75岁初治老年非小细胞肺癌患者，给以口服长春瑞滨软胶囊50 mg每次，每周3次单药节拍化疗，观察临床疗效、不良反应及总生存期和无进展生存期。结果 全部患者疗效评价CR 1例（1.8%），PR 9例（16.1%），ORR为17.9%；SD 22例（39.3%），并且稳定时间人均达12周以上，DCR达57.2%；中位无进展生存期5月（3~22月），中位总生存期9月（4~31月），1年生存率为35.7%（20/56），2年生存率为16.1%（9/56），3~4级不良反应出现较少。结论 应用长春瑞滨软胶囊单药节拍化疗安全可靠，可有效改善生活质量，为老年非小细胞肺癌患者临床综合治疗决策提供了新的思路
Full-Text
